Once-a-Month shot could ease anemia for kidney patients
NCT ID NCT00661388
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a monthly injection of Mircera in 75 adults with chronic kidney disease who were not yet on dialysis and had anemia. The goal was to see if the drug could safely raise and maintain hemoglobin levels. Results showed improvement in hemoglobin during the evaluation period.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- methoxy polyethylene glycol-epoetin beta (Mircera)
- What this could lead to
- If successful, this could provide a convenient once-monthly treatment option for managing anemia in pre-dialysis patients.
- What could go wrong
- This is a completed Phase 3 trial, but results may not apply to all patients. Risks include high blood pressure and bleeding, and the treatment does not cure kidney disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
75 people
The number who actually took part.
- Start date
-
Aug 2008
- Finished
-
Dec 2010
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * adult patients, \>=18 years of age; * chronic renal anemia; * predialysis stage; * no ESA therapy during previous 3 months. Exclusion Criteria: * transfusion of red blood cells during previous 2 months; * poorly controlled hypertension requiring hospitalization in previous 6 months; * significant acute or chronic bleeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Ankara, 06100, Turkey (Türkiye)
-
Study site
Denizli, 20100, Turkey (Türkiye)
-
Study site
Edirne, 22030, Turkey (Türkiye)
-
Study site
Istanbul, 34000, Turkey (Türkiye)
-
Study site
Istanbul, 34377, Turkey (Türkiye)
-
Study site
Istanbul, 34381, Turkey (Türkiye)
-
Study site
Istanbul, 34390, Turkey (Türkiye)
-
Study site
Kahramanmaraş, 46100, Turkey (Türkiye)
-
Study site
Konya, 42770, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can IV iron boost blood levels and daily energy for mothers before and after delivery?
- Iron boost before heart surgery may cut need for donor blood
- Can scheduled malaria drugs shield infants from severe illness?
- Can a simple preventive drug cut malaria and anemia in infants?
- Can catching anemia months before joint surgery speed recovery?
- Can a simple blood test predict surgery risks?